KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Non-Current Deferred Tax Liability (2020 - 2025)

Historic Non-Current Deferred Tax Liability for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to $9.7 million.

  • AbCellera Biologics' Non-Current Deferred Tax Liability fell 2376.18% to $9.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.7 million, marking a year-over-year decrease of 2376.18%. This contributed to the annual value of $10.1 million for FY2024, which is 8697.51% down from last year.
  • AbCellera Biologics' Non-Current Deferred Tax Liability amounted to $9.7 million in Q3 2025, which was down 2376.18% from $10.1 million recorded in Q2 2025.
  • In the past 5 years, AbCellera Biologics' Non-Current Deferred Tax Liability registered a high of $77.2 million during Q4 2023, and its lowest value of $9.7 million during Q3 2025.
  • Moreover, its 5-year median value for Non-Current Deferred Tax Liability was $33.2 million (2023), whereas its average is $30.3 million.
  • Its Non-Current Deferred Tax Liability has fluctuated over the past 5 years, first skyrocketed by 6554.28% in 2022, then crashed by 8697.51% in 2024.
  • AbCellera Biologics' Non-Current Deferred Tax Liability (Quarter) stood at $37.4 million in 2021, then soared by 65.54% to $61.9 million in 2022, then increased by 24.65% to $77.2 million in 2023, then tumbled by 86.98% to $10.1 million in 2024, then dropped by 3.06% to $9.7 million in 2025.
  • Its Non-Current Deferred Tax Liability was $9.7 million in Q3 2025, compared to $10.1 million in Q2 2025 and $10.1 million in Q1 2025.